

**DISHMAN PHARMACEUTICALS AND CHEMICALS LIMITED**

Bhadr-Raj Chambers, Swastik Cross Roads, Navrangpura, Ahmedabad-380 009

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st DECEMBER, 2010

(Rupees in Lakhs)

Sr. No.	PARTICULARS	STANDALONE					CONSOLIDATED				
		For the quarter ended 31-12-2010	For the Quarter ended 31-12-2009	For the Nine Months ended 31-12-2010	For the Nine Months ended 31-12-2009	For the Year ended 31-03-2010	For the quarter ended 31-12-2010	For the Quarter ended 31-12-2009	For the Nine Months ended 31-12-2010	For the Nine Months ended 31-12-2009	For the Year ended 31-03-2010
		Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	a) Net Sales/Income From Operations	9,357.82	9,130.86	25,076.70	25,799.09	35,260.88	23,176.17	22,229.77	64,644.19	66,744.31	91,535.74
	b) Other Operating Income	232.59	30.17	293.84	80.81	315.28	612.83	318.08	3,677.38	2,452.01	2,693.46
	c) Income from Associates	-	-	-	-	-	0.28	0.08	3.82	2.94	4.91
	<b>Total Income (a+b+c)</b>	<b>9,590.40</b>	<b>9,161.03</b>	<b>25,370.54</b>	<b>25,879.91</b>	<b>35,576.16</b>	<b>23,789.28</b>	<b>22,547.93</b>	<b>68,325.39</b>	<b>69,199.26</b>	<b>94,234.11</b>
2	<b>Expenditure</b>										
	a) (Increase)/Decrease in Stock in trade and work in progress	(297.80)	503.53	(1,114.55)	931.85	1,287.47	(1,165.04)	38.30	(2,231.33)	(1,442.20)	700.99
	b) Consumption of Raw Materials	4,225.46	3,171.83	11,363.82	8,818.32	12,280.46	8,346.73	4,173.22	20,273.69	16,510.00	23,177.78
	c) Purchase of traded goods	40.46	15.25	81.18	108.40	246.97	1,196.43	1,692.27	1,891.33	2,436.04	3,796.36
	d) Employees Cost	1,267.03	997.18	3,411.77	2,859.76	3,371.31	7,284.27	6,765.27	20,530.38	20,907.24	25,405.80
	e) Depreciation	636.78	501.86	1,969.46	1,536.59	2,064.10	1,709.55	1,406.59	5,001.58	4,594.59	5,941.60
	f) Other Expenditure	1,744.77	1,526.12	4,808.38	4,298.56	6,347.98	4,978.89	4,429.95	13,504.51	12,904.50	18,077.06
	<b>g) Total</b>	<b>7,616.70</b>	<b>6,715.78</b>	<b>20,520.05</b>	<b>18,553.48</b>	<b>25,598.29</b>	<b>22,350.83</b>	<b>18,505.60</b>	<b>58,970.16</b>	<b>55,910.17</b>	<b>77,099.59</b>
3	<b>Profit from Operations before Other Income, Interest and Exceptional Items (1-2)</b>	<b>1,973.70</b>	<b>2,445.25</b>	<b>4,850.49</b>	<b>7,326.42</b>	<b>9,977.86</b>	<b>1,438.45</b>	<b>4,042.33</b>	<b>9,355.23</b>	<b>13,289.09</b>	<b>17,134.52</b>
4	Other Income	-	-	-	-	-	-	-	-	-	-
5	<b>Profit before Interest and Exceptional Items (3+4)</b>	<b>1,973.70</b>	<b>2,445.25</b>	<b>4,850.49</b>	<b>7,326.42</b>	<b>9,977.86</b>	<b>1,438.45</b>	<b>4,042.33</b>	<b>9,355.23</b>	<b>13,289.09</b>	<b>17,134.52</b>
6	Interest & Financial Charges (Net)	743.53	360.38	1,878.59	1,358.04	2,037.18	1,334.38	853.17	3,109.61	2,875.92	3,876.73
7	<b>Profit after Interest but before Exceptional Items (5-6)</b>	<b>1,230.17</b>	<b>2,084.88</b>	<b>2,971.90</b>	<b>5,968.38</b>	<b>7,940.69</b>	<b>104.07</b>	<b>3,189.16</b>	<b>6,245.62</b>	<b>10,413.17</b>	<b>13,257.79</b>
8	Exceptional Items	-	-	-	-	-	-	-	-	-	-
9	<b>Profit (+)/ Loss (-) from Ordinary Activities before tax (7+8)</b>	<b>1,230.17</b>	<b>2,084.88</b>	<b>2,971.90</b>	<b>5,968.38</b>	<b>7,940.69</b>	<b>104.07</b>	<b>3,189.16</b>	<b>6,245.62</b>	<b>10,413.17</b>	<b>13,257.79</b>
10	Tax expense	157.89	231.32	326.01	663.83	903.82	(70.57)	(63.48)	405.60	754.89	1,495.25
11	<b>Net Profit (+)/ Loss (-) from Ordinary Activities after tax (9-10)</b>	<b>1,072.28</b>	<b>1,853.55</b>	<b>2,645.88</b>	<b>5,304.55</b>	<b>7,036.87</b>	<b>174.64</b>	<b>3,252.64</b>	<b>5,840.02</b>	<b>9,658.28</b>	<b>11,762.54</b>
12	a) Extraordinary Items (net of tax expense)	-	-	-	-	-	-	-	-	-	-
	b) Prior Period Expenses	3.87	4.55	(12.69)	12.99	(110.00)	6.89	(99.69)	118.02	(47.76)	(171.68)
	c) Short provision of Income Tax	-	1.03	-	40.70	39.52	-	44.74	-	84.40	196.72
13	<b>Net Profit (+)/ Loss (-) for the period (11-12)</b>	<b>1,068.41</b>	<b>1,847.97</b>	<b>2,658.57</b>	<b>5,250.86</b>	<b>7,107.35</b>	<b>167.75</b>	<b>3,307.59</b>	<b>5,722.00</b>	<b>9,621.64</b>	<b>11,737.50</b>
14	Paid-up Equity Share Capital (Face Value of Rs 2/- per equity share)	1,613.94	1,613.94	1,613.94	1,613.94	1,613.94	1,613.94	1,613.94	1,613.94	1,613.94	1,613.94
15	Reserves Excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	59,507.70	-	-	-	-	75,480.04
16	Basic and Diluted EPS (before & after Extraordinary Items)	-	-	-	-	-	-	-	-	-	-
	Basic EPS (in Rs. Not annualised)	1.32	2.29	3.29	6.51	8.81	0.21	4.10	7.09	11.92	14.55
	Diluted EPS (in Rs. Not annualised)	1.32	2.27	3.29	6.46	8.74	0.21	4.07	7.09	11.83	14.44
17	<b>Public Shareholding</b>										
	- Number of Equity Shares	31,555,667	31,655,667	31,555,667	31,655,667	31,555,667	31,555,667	31,655,667	31,555,667	31,655,667	31,555,667
	- Percentage of Shareholding	39.10	39.23	39.10	39.23	39.10	39.10	39.23	39.10	39.23	39.10
18	<b>Promoters and promoter group</b>										
	a) Pledged/Encumbered										
	- Number of Equity Shares	-	2,500,000	-	2,500,000	2,500,000	-	2,500,000	-	2,500,000	2,500,000
	- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)		5.10%		5.10%	5.09%		5.10%		5.10%	5.09%
	- Percentage of Shares (as a % of the total share capital of the company)		3.10%		3.10%	3.10%		3.10%		3.10%	3.10%
	b) Non-encumbered										
	- Number of Equity Shares	49,141,469	46,541,469	49,141,469	46,541,469	46,641,469	49,141,469	46,541,469	49,141,469	46,541,469	46,641,469
	- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	100.00%	94.90%	100.00%	94.90%	94.91%	100.00%	94.90%	100.00%	94.90%	94.91%
	- Percentage of Shares (as a % of the total share capital of the company)	60.90%	57.67%	60.90%	57.67%	57.80%	60.90%	57.67%	60.90%	57.67%	57.80%

Segment wise Revenue ,Result and Capital Employed

Sr. No	PARTICULARS	For the quarter ended	For the Quarter ended	For the Nine Months ended	For the Nine Months ended	For the Year ended	For the quarter ended	For the Quarter ended	For the Nine Months ended	For the Nine Months ended	For the Year ended
		31-12-2010	31-12-2009	31-12-2010	31-12-2009	31-03-2010	31-12-2010	31-12-2009	31-12-2010	31-12-2009	31-03-2010
		Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>1</b>	<b>Segment Revenue</b>										
	(a) CRAMS	6,860.09	7,032.92	17,942.65	19,311.81	25,701.86	15,817.83	16,072.25	46,167.68	49,074.16	66,293.81
	(b) Marketable Molecules (MM)	2,497.72	2,097.94	7,134.05	6,487.28	9,559.03	7,358.34	6,157.52	18,476.51	17,670.15	25,241.93
	(c) Others	-	-	-	-	-	-	-	-	-	-
	<b>Total</b>	<b>9,357.82</b>	<b>9,130.86</b>	<b>25,076.70</b>	<b>25,799.09</b>	<b>35,260.88</b>	<b>23,176.17</b>	<b>22,229.77</b>	<b>64,644.19</b>	<b>66,744.31</b>	<b>91,535.74</b>
	Less: Inter-segment Revenue	-	-	-	-	-	-	-	-	-	-
	<b>Net Sales /Income from Operation</b>	<b>9,357.82</b>	<b>9,130.86</b>	<b>25,076.70</b>	<b>25,799.09</b>	<b>35,260.88</b>	<b>23,176.17</b>	<b>22,229.77</b>	<b>64,644.19</b>	<b>66,744.31</b>	<b>91,535.74</b>
<b>2</b>	<b>Segment Results</b> {(Profit)(+)/(Loss)(-) before tax and interest from each segment}										
	(a) CRAMS*	1,794.04	2,020.06	4,236.41	6,017.59	8,130.38	849.31	3,002.88	7,107.03	10,397.88	13,443.99
	(b) Marketable Molecules (MM)*	179.65	425.19	614.08	1,308.83	1,797.48	588.93	1,039.45	2,244.46	2,891.21	3,635.73
	(c) Others	-	-	-	-	-	-	-	-	-	-
	<b>Total</b>	<b>1,973.70</b>	<b>2,445.25</b>	<b>4,850.49</b>	<b>7,326.42</b>	<b>9,927.86</b>	<b>1,438.24</b>	<b>4,042.33</b>	<b>9,351.49</b>	<b>13,289.09</b>	<b>17,079.72</b>
	Less: i) Interest	743.53	360.38	1,878.59	1,358.04	2,037.18	1,334.38	853.17	3,109.61	2,875.92	3,876.73
	ii) Other un-allocable expenditure net off un-allocable income	-	-	-	-	(50.00)	(0.21)	-	(3.74)	-	(54.80)
	<b>Total Profit Before Tax</b>	<b>1,230.17</b>	<b>2,084.88</b>	<b>2,971.90</b>	<b>5,968.38</b>	<b>7,940.69</b>	<b>104.07</b>	<b>3,189.16</b>	<b>6,245.62</b>	<b>10,413.17</b>	<b>13,257.79</b>
<b>3</b>	<b>Capital Employed (Segment Assets-Segment liabilities)</b>										
	(a) CRAMS	47,014.70	41,597.46	47,014.70	41,597.46	51,605.07	85,552.97	82,169.68	85,552.97	82,169.68	86,697.00
	(b) Marketable Molecules (MM)	12,483.24	13,084.96	12,483.24	13,084.96	11,398.97	25,421.88	28,727.23	25,421.88	28,727.23	24,968.34
	(c) Others	59,410.68	50,013.83	59,410.68	50,013.83	44,411.89	61,766.69	47,880.99	61,766.69	47,880.99	44,155.03
	<b>Total</b>	<b>118,908.62</b>	<b>104,696.25</b>	<b>118,908.62</b>	<b>104,696.25</b>	<b>107,415.93</b>	<b>172,741.54</b>	<b>158,777.90</b>	<b>172,741.54</b>	<b>158,777.90</b>	<b>155,820.37</b>

\* Includes Forex (Loss) / Gain

On behalf of the Board

Place: Ahmedabad

Date: 11th February, 2011

Janmejay R Vyas

Chairman & Managing Director